OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
Trial details
- Registry ID
- NCT04314934
- Phase
- Phase 2, Phase 3
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Blarcamesine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| OLE of Phase 2b/3 Study ANAVEX2-73-AD-004NCT04314934 | AVXL | Phase 2, Phase 3 | Completed | 2024-06-14Actual |
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |